Astellas Pharma Inc. Stock Deutsche Boerse AG
Stocks
YPHA
US04623U1025
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.00 EUR | -0.90% |
|
-1.79% | -0.90% |
| 07-12 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,853B 23.73B 20.74B 19.14B 17.64B 33.25B 2,286B 33.99B 229B 89.98B 1,119B 89.13B 87.18B | P/E 2027 * |
11.2x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,710B 22.85B 19.97B 18.42B 16.98B 32.01B 2,200B 32.72B 220B 86.62B 1,078B 85.8B 83.92B | EV / Sales 2027 * |
1.64x | EV / Sales 2028 * | 1.63x |
| Free-Float |
97.66% | Yield 2027 * |
3.74% | Yield 2028 * | 3.86% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.90% | ||
| 1 week | -1.79% | ||
| Current month | -2.65% | ||
| 1 month | -4.35% | ||
| 3 months | -16.67% | ||
| 6 months | -10.57% | ||
| Current year | -0.90% |
| 1 week | 11 |  | 11.1 |
| 1 month | 11 | | 11.5 |
| Current year | 10.8 | | 14.1 |
| 1 year | 7.95 | | 14.1 |
| 3 years | 7.5 | | 14.1 |
| 5 years | 7.5 | | 15.6 |
| 10 years | 7.5 | | 16.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 2023-02-09 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 2023-10-31 |
Tatjana Dragovic
CMP | Compliance Officer | - | 2025-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 2023-02-09 |
Naoki Okamura
BRD | Director/Board Member | 63 | 2019-05-31 |
| Director/Board Member | 58 | 2023-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.90% | -1.79% | - | - | 23.73B | |
| +0.85% | -0.80% | +52.79% | +161.33% | 1,051B | |
| +1.23% | -1.53% | +54.58% | +59.08% | 609B | |
| +0.04% | +2.58% | +34.47% | +86.33% | 450B | |
| +0.78% | -0.71% | +29.28% | +24.10% | 330B | |
| +1.41% | +0.58% | +35.44% | +40.67% | 284B | |
| -0.27% | -1.87% | +22.34% | +22.51% | 263B | |
| -1.76% | +2.37% | -20.43% | -38.00% | 223B | |
| -1.42% | +0.80% | +24.27% | +57.50% | 198B | |
| -1.48% | +3.43% | +24.08% | +71.67% | 167B | |
| Average | -0.15% | +0.54% | +28.54% | +53.91% | 397.23B | |
| Weighted average by Cap. | +0.36% | +0.02% | +37.51% | +79.63% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,258B 13.91B 12.15B 11.21B 10.34B 19.48B 1,339B 19.92B 134B 52.72B 656B 52.23B 51.08B | 2,074B 12.78B 11.16B 10.3B 9.5B 17.9B 1,230B 18.3B 123B 48.43B 603B 47.98B 46.92B |
| Net income | 345B 2.12B 1.85B 1.71B 1.58B 2.97B 204B 3.04B 20.45B 8.04B 100B 7.97B 7.79B | 328B 2.02B 1.77B 1.63B 1.5B 2.83B 195B 2.89B 19.48B 7.66B 95.32B 7.59B 7.42B |
| Net Debt | -144B -886M -774M -715M -659M -1.24B -85.35B -1.27B -8.54B -3.36B -41.8B -3.33B -3.26B | -478B -2.94B -2.57B -2.37B -2.19B -4.12B -283B -4.21B -28.36B -11.15B -139B -11.05B -10.81B |
| Date | Price | Change |
|---|---|---|
| 26-07-17 | €11.00 | -0.90% |
| 26-07-16 | €11.10 | +0.91% |
| 26-07-15 | €11.00 | -0.90% |
| 26-07-14 | €11.10 | +0.91% |
| 26-07-13 | €11.00 | -1.79% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
- YPHA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
